Expert Insights on Biologics for Treating Psoriasis: Interview Discussions
In the treatment of moderate to severe psoriasis and psoriatic arthritis, biologics have emerged as a safe and effective option for many individuals. These injectable medications, made from living cells or through a biological process, work by blocking specific steps in the immune pathway that cause inflammation in psoriasis.
Biologics are categorised into four main types based on their mechanism of action: TNF-alpha blockers, IL-12/23 inhibitors, IL-17 inhibitors, and IL-23 inhibitors. Each category has distinct dosing, side effects, and effectiveness profiles.
TNF-alpha blockers, such as adalimumab (Humira), etanercept (Enbrel), and infliximab, are administered via injection or infusion. Dosing schedules vary by drug, with examples like infliximab being given as an IV infusion at weeks 0, 2, and 6, and then every 8 weeks. Common side effects include injection site reactions, headaches, and an increased risk of infections, with serious risks such as reactivation of tuberculosis and malignancies, although rare.
IL-12/23 inhibitors, like ustekinumab, are administered either subcutaneously or intravenously. Initial doses are typically followed by maintenance doses every 12 weeks. Ustekinumab may cause injection site reactions and has a lower risk of tuberculosis reactivation compared to TNF-alpha blockers, but it might be associated with major cardiovascular events.
IL-17 inhibitors, such as secukinumab and ixekizumab, are generally well-tolerated but may cause injection site reactions and have a lower risk of infections compared to TNF-alpha blockers.
IL-23 inhibitors, including guselkumab and risankizumab, are also administered subcutaneously with dosing tailored to each drug. They are generally well-tolerated, with mild side effects, and their effectiveness with lower side effects compared to older biologics makes them a preferred option for some patients.
The choice of biologic depends on individual patient factors, including comorbidities, previous treatments, and specific disease characteristics. For instance, the IL-12/23 inhibitor ustekinumab (Stelara) treats both psoriasis and psoriatic arthritis, while IL-17 inhibitors like secukinumab (Cosentyx) and ixekizumab (Taltz) are also effective for psoriasis treatment.
It's important to note that biologics can lead to a favorable reduction in PASI scores in people with psoriasis, but they may become less effective over time. If a biologic is ineffective or stops working, a dermatologist may change the medication to another in the same or different class.
Before administering a biologic, a person should clean their hands and the injection site thoroughly. To administer a biologic, a person places the auto-injector flush to the skin and presses the releaser to deliver the medication. After administering a biologic, the individual can clean the skin again if there is blood and apply an adhesive bandage.
Nursing support is available from some companies for self-administration of biologics. People can self-inject biologics at home using auto-injector pens. However, biologics are not appropriate for people with active cancer, an active infection, or those who are systemically unwell.
In conclusion, biologics offer a promising treatment option for those suffering from psoriasis and psoriatic arthritis. By understanding the distinct dosing, side effects, and effectiveness profiles of each category, patients can make informed decisions in consultation with their healthcare providers.
- Individuals seeking treatment for moderate to severe psoriasis and psoriatic arthritis may find relief in biologics, which work by blocking immune pathway steps causing inflammation.
- TNF-alpha blockers, such as Humira, Enbrel, and Remicade, are administered through injections or infusions and have distinct dosing, side effects, and effectiveness profiles, including the risk of infections and serious side effects.
- The IL-12/23 inhibitor Stelara (ustekinumab) treats both psoriasis and psoriatic arthritis; it may cause injection site reactions and has a lower risk of tuberculosis reactivation compared to TNF-alpha blockers but might be associated with major cardiovascular events.
- Therapies-and-treatments like Cosentyx (secukinumab) and Taltz (ixekizumab), classified as IL-17 inhibitors, are generally well-tolerated but may cause injection site reactions and have a lower risk of infections compared to TNF-alpha blockers.
- Health-and-wellness practitioners might consider guselkumab or risankizumab, IL-23 inhibitors, for their patients, as they are generally well-tolerated with mild side effects and perceived as a preferred option due to their effectiveness with lower side effects compared to older biologics.
